Table 1. Characteristicsa of nonmyeloablative hematopoietic cell transplant (HCT) recipients.
| Characteristic | No. of patients |
|---|---|
| Total no. of patients | 84 |
| Age (years) | 61.7 (20.0-73.1) |
| Male | 52 (62%) |
| Cancer diagnosis | |
| Non-Hodgkin lymphoma | 28 (33%) |
| Chronic lymphocytic leukemia | 16 (19%) |
| Acute myeloid leukemia | 12 (14%) |
| Multiple myeloma | 8 (10%) |
| Myelodysplastic syndrome | 7 (8%) |
| Myeloproliferative disorders | 4 (5%) |
| Acute lymphocytic leukemia | 3 (4%) |
| Other | 6 (7%) |
| HCT comborbidity indexb | |
| 0 | 8 (10%) |
| 1 – 2 | 13 (15%) |
| 3 – 4 | 31 (37%) |
| ≥ 5 | 30 (36%) |
| End organ dysfunctionc | |
| Renal dysfunction d | 11 (13%) |
| Liver dysfunctione | 12 (14%) |
| Postgrafting immunosuppression concomitant with MMF | |
| Cyclosporine | 58 (69%) |
| Tacrolimus | 26 (31%) |
| Sirolimus and calcineurin inhibitor | 13 (15%) |
aCategorical data presented as number of participants meeting stated criteria; continuous data presented as median (min-max); bHCT-Comorbidity index was assigned to 82 patients; c1 patient, included in both values below, had both renal and liver dysfunction; dcreatinine clearance < 60 ml/min, calculated with Cockroft Gault equation using actual body weight; etotal bilirubin > than 2 times laboratory upper normal limits, alanine aminotransferase or aspartate aminotransferase > than 3 times laboratory upper normal limits.